Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Trial of Anlotinib in Progressive, Recurrent, and Refractory Sarcoma in Children

NCT04659733 is registered in ClinicalTrials.gov with Yizhuo Zhang as lead sponsor.

NCT NCT04659733
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04659733 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Trial of Anlotinib in Progressive, Recurrent, and Refractory Sarcoma in Children
Lead sponsor
Yizhuo Zhang
Phase
Phase 1
Overall status
Unknown status
Start date
December 30, 2020
Completion date
December 30, 2022
Enrollment
36 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

sarcoma